More Support for “Watch-and-Wait” Approach in Some With Resectable Rectal Cancer
Suspected local disease regrowth was seen in 23% of patients with rectal cancer observed following a near or complete clinical response to neoadjuvant therapy.
All articles by Susan Moench, PhD, PA-C
Multiple Factors Linked to Hospital Readmission Following Pancreatectomy
Results of this study showed no improvement in the rate of 30-day hospital readmission for patients with cancer undergoing pancreatectomy between 2005 and 2011.
Sociodemographic Factors Influenced Survival in Young Adults With Colorectal Cancer
In this study, a young adult was defined as an individual who was 40 years or younger.
No Local Control or OS Benefit Seen With RT Dose Escalation in Inoperable Esophageal Cancer
In this study, patients were randomly assigned to receive standard-dose RT or standard-dose RT plus an integrated RT boost to the primary tumor.
Study Finds Atezolizumab Plus Bevacizumab Prolongs Maintenance of QoL Compared With Sorafenib in Certain Patients With HCC
In this study, deterioration in specific PROs required a drop of at least 10 points from baseline.
Avelumab Maintenance: No OS Benefit vs Continued Chemotherapy in HER2-Negative Gastrointestinal Cancers
Fewer treatment-related grade 3 or higher adverse events were reported in the avelumab arm compared with the chemotherapy arm.
Longer Maintenance of QoL in BRAF V600E-Mutant Metastatic Colorectal Cancer With Triplet Regimen vs an Irinotecan-Based Regimen
The randomized, phase 3 BEACON CRC trial was a 3-arm study conducted in patients with pretreated metastatic CRC characterized by a BRAF V600E mutation.
Study Reveals Differences Between the Genomic Profiles of Primary Tumors and Metastatic Lesions in Intrahepatic Cholangiocarcinoma
Previous genomic profiling studies have identified potentially targetable alterations in IDH1 and FGFR2 in primary tumor specimens of some patients with IHCC.
Addition of Pegilodecakin to FOLFOX Did Not Improve OS in Metastatic Pancreatic Cancer
Promising results from an earlier-phase study of FOLFOX plus pegilodecakin in metastatic PDAC refractory to gemcitabine provided a rationale for this study.
Progression-Free Rate With Maintenance Therapy in Some Esophageal or Gastric Cancers May Be Associated With PD-L1 Level
In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.
Next post in Stomach Disorders
